Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points

Journal of Clinical Oncology

Volumn 20, Issue 16, 2002, Pages 3445-3453

  Mehta, Minesh P ^a   Shapiro, William R ^a   Glantz, Michael J ^a   Patchell, Roy A ^a   Weitzner, Michael A ^a   Meyers, Christina A ^a   Schultz, Christopher J ^a   Roa, Wilson H ^a   Leibenhaut, Mark ^a   Ford, Judith ^a   Curran, Walter ^a   Phan, See ^a   Smith, Jennifer A ^a   Miller, Richard A ^a   Renschler, Markus F ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM TEXAPHYRIN;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COGNITION; CRANIAL IRRADIATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METALLOPORPHYRINS; MIDDLE AGED; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0037102391     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.07.500     Document Type: Article

References (25)

1. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials
2. Identification of prognostic factors in patients with brain metastases: A review of 1292 patients
3. Prognostic factors in brain metastases: Should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?
4. Texaphyrins: Synthesis and development of a novel class of therapeutic agents
5. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species
6. Pulse radiolytic studies of metallotexaphyrins in the presence of oxygen: Relevance of the equilibrium with superoxide anion to the mechanism of action of the radiation sensitizer motexafin gadolinium (Gd-Tex2+, Xcytrin)
7. Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity
8. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer
9. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging
10. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases
11. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases
12. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects
13. Evaluation of tumor measurements in oncology: Use of film-based and electronic techniques
14. Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability
15. The Hopkins Verbal Learning Test: Development of a new memory test with six equivalent forms
16. Instruction/Owner's Manual: Instructions for the 32025 Grooved Pegboard Test
17. The Functional Assessment of Cancer Therapy Scale: Development and validation of the general measure
18. The Functional Assessment of Cancer Therapy (FACT) scale: Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors
19. Nonparametric estimation from incomplete observations
20. Relation between local result and total dose of radiotherapy for brain metastases
21. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation